Published in J Immunother on February 06, 2012
Immunotherapy for ovarian cancer. Curr Treat Options Oncol (2015) 0.89
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) (2015) 0.83
Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J (2015) 0.82
Surgical immune interventions for solid malignancies. Am J Surg (2016) 0.75
Proceedings of the Annual Symposium & Plenary Session on Regenerative Medicine (PASRM). J Stem Cells Regen Med (2012) 0.75
Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology (2017) 0.75
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods (1991) 4.55
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol (2006) 2.70
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A (1989) 2.11
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother (2007) 2.05
Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol (1993) 1.39
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol (2003) 1.36
Cell surface phenotype of a cloned line of human natural killer cells. J Immunol (1982) 1.35
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine (2000) 1.01
CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol (2006) 1.00
Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol (1994) 0.94
Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol (2007) 0.93
Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res (1998) 0.91
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91
Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother (2000) 0.91
Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica (2007) 0.90
Context of MUC1 epitope: immunogenicity. Oncol Rep (2007) 0.90
Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin Diagn Lab Immunol (1997) 0.90
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest (2008) 0.90
Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand J Immunol (2007) 0.87
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res (2000) 0.81
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study. Immunol Invest (2009) 0.80
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol (2007) 1.69
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Resource loss, coping, alcohol use, and posttraumatic stress symptoms among survivors of Hurricane Katrina: a cross-sectional study. Am J Disaster Med (2009) 1.07
CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol (2006) 1.00
Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study. Arthritis Res Ther (2013) 0.99
Desmoid tumors of the right rectus abdominus muscle in postpartum women. Arch Gynecol Obstet (2008) 0.98
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother (2009) 0.95
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res (2011) 0.93
MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One (2012) 0.93
HIV risk and the alcohol environment: advancing an ecological epidemiology for HIV/AIDS. Alcohol Res Health (2010) 0.93
A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92
Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol (2004) 0.91
A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother (2010) 0.90
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest (2008) 0.90
B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma (2008) 0.90
Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med (2002) 0.89
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate. Virology (2007) 0.86
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. Hepatology (2010) 0.84
Geospatial methods for identification of core groups for HIV/AIDS. Subst Use Misuse (2008) 0.84
Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. J Cancer Res Clin Oncol (2013) 0.83
Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative. Am J Epidemiol (2013) 0.83
Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. Clin Proteomics (2012) 0.83
MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics (2011) 0.82
Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis (2012) 0.81
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother (2011) 0.81
Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics (2012) 0.81
Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity. Mol Cancer Ther (2009) 0.81
Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. Virology (2008) 0.81
Designation as "unfit for open repair" is associated with poor outcomes after endovascular aortic aneurysm repair. Circ Cardiovasc Qual Outcomes (2013) 0.81
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study. Immunol Invest (2009) 0.80
Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clin Immunol (2013) 0.80
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy (2012) 0.80
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. Clin Immunol (2008) 0.79
Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. J Proteomics (2012) 0.79
Findings from panoramic radiographs of the edentulous population and review of the literature. Quintessence Int (2007) 0.79
Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics. Anal Chem (2010) 0.79
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. Immunol Invest (2008) 0.78
Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics. OMICS (2011) 0.78
Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol (2012) 0.78
Moxifloxacin associated vanishing bile duct syndrome. J Clin Gastroenterol (2010) 0.78
Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. Immunopharmacol Immunotoxicol (2010) 0.77
Prevention of human adenocarcinoma with CpG-ODN in a mouse model. Oncol Lett (2012) 0.77
A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation. PLoS One (2011) 0.77
R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma. Br J Haematol (2008) 0.76
Characteristics of women with gynecologic cancer who enter clinical trials. J Reprod Med (2005) 0.76
Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin Immunother (2014) 0.75
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology (2013) 0.75
MHC-restricted presentation of a single repeat of MUC1 mucin. Immunol Invest (2007) 0.75
Holistic leadership. Beginnings (2012) 0.75
A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology (Williston Park) (2005) 0.75
A case of Merkel cell carcinoma. Oncology (Williston Park) (2008) 0.75
A woman with primary breast cancer and a solitary sternal metastasis. Oncology (Williston Park) (2006) 0.75
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study. Immunol Invest (2010) 0.75
A new approach to functional near-infrared technology. IEEE Eng Med Biol Mag (2007) 0.75
My holistic workplace. Beginnings (2011) 0.75
The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park) (2008) 0.75
Tucaresol down-modulation of MUC1-stimulated human mononuclear cells. Immunol Invest (2013) 0.75
Holistic nursing across my specialty areas of practice. Beginnings (2009) 0.75